ArticleApplied biochemistry and biotechnology2026
Impact of Xylooligosaccharides Containing Soluble Lignin Fractions from Birch on Prebiotic Activity by In Vitro Fecal Fermentation of Smoking-Linked Dysbiotic Subhealthy Gut Microbiota.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study evaluated the impact of two xylo-oligosaccharide (XOS) samples on gut microbiota from sub-healthy individuals with smoking-associated gut dysbiosis via in vitro fermentation. Sample S1 contained partially retained soluble small-molecular lignin (over 2%) with molecular weights of Mn = 685 Da and Mw = 1264 Da, whereas S2 was a highly purified XOS preparation with negligible soluble lignin content. Compared to S2, the S1 treatment resulted in a higher relative abundance of beneficial genera such as Bifidobacterium(6.6% vs. 5.4%) and Megamonas(46.3% vs. 32.3%), and a lower abundance of potentially harmful bacteria including Fusobacterium(6.7% vs. 21.6%) and Escherichia-Shigella(1.6% vs. 8.7%). Moreover, fermentation with S1 resulted in increased production of short-chain fatty acids, particularly acetic acid, indicating improved microbial metabolic activity and gut health potential. Additionally, S1 achieved 63.5% DPPH scavenging at 2 × 10
Indexed as
Identifiers
42479389What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.